Jean-Charles Soria/LinkedIn
Aug 1, 2025, 16:47
Jean-Charles Soria: Liquid Biopsies in CRC
Jean-Charles Soria, Amgen’s senior vice president of Oncology within Global Development, shared an article on LinkedIn:
“Liquid biopsies in CRC
Serial MRD monitoring:
- Detects recurrence 8–11 months earlier than imaging
- Improves sensitivity from 40–50% to 80–90%
- Helps monitor ACT response
Liquid tumor-agnostic assays are evolving: now integrating
- Methylation
- Fragmentomics
- Mutations.”
Title: Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy
Authors: B. Martínez-Castedo, D.G. Camblor, J. Martín-Arana, J.A. Carbonell-Asins, B. García-Micó, V. Gambardella, M. Huerta, S. Roselló, D. Roda, F. Gimeno-Valiente, A. Cervantes, N. Tarazona
Read the Full Article.
More posts featuring Jean-Charles Soria.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 2, 2025, 00:00
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32